Abstract:Abstract Background and objectives: Motivated from a study on breast cancer, we consider the problem of evaluating a statistical hypothesis when some model characteristics are potentially non or weakly identifiable from observed data. Such scenarios are common in longitudinal studies for evaluating a covariate effect when dropouts may be informative. The hypothesis related to treatment effects may not be testable nonparametrically, with untestable model restrictions necessary for inference. A popular approach is to assume a finite dimensional model and to fix a minimal set of parameters, called sensitivity parameters, conditional upon which hypothesized parameters are assumed identifiable. These profile models, viewed as a functional of the secondary or sensitivity parameters, form the basis of sensitivity analysis. In the current literature, however, inference regarding significance of the covariates is ad hoc, ignoring that multiple tests are conducted and that the working model may be misspecified. Methods and results: In this paper, we propose conservatively testing the null hypothesis of interest across the support of the sensitivity parameters using an infimum test statistic. The test must account for the facts that inferences are carried out simultaneously across the entire range of the sensitivity parameters and that the model may be misspecified under certain values of the sensitivity parameters, as might occur if a nonignorable model is fit, when, in reality, missingness is ignorable. We characterize the limiting distribution of the statistic as a functional of processes in the sensitivity parameters, which involves a careful theoretical analysis of its behavior under model misspecification. In practice, we suggest a simple yet flexible resampling procedure to implement the infimum test as well as to construct confidence bands for simultaneous pointwise tests across all values of the sensitivity parameters. The methodology's practical utility is illustrated in simulations and an analysis of quality-of-life outcomes from a longitudinal study on breast cancer. Interestingly in this example, a covariate effect on cancer outcomes is detected over a wide range of the sensitivity parameter when a Wald test that assumes identifiability fails. Implications and next steps: The key implication of this work is that the hypothesis of interest can be conservatively evaluated across the support of the sensitivity parameters using an infimum test statistic over the space of these parameters. A key assumption of this paper is that the working model is finite dimensional although the full specification of distribution of the data is not required. The methodology should be broadly applicable to infinite dimensional models, such as survival models for censored data. This extension is the focus of current research work. Citation Information: Cancer Epidemiol Biomarkers Prev 2011;20(10 Suppl):A6.

Sensitivity Analysis for a Partially Missing Binary Outcome in a Two-Arm Randomized Clinical Trial.

Sensitivity analysis for a partially missing binary outcome in a two‐arm randomized clinical trial

Missing Data Handling Methods in Medical Device Clinical Trials

Sensitivity analysis in longitudinal clinical trials via distributional imputation

Analysis of an Incomplete Binary Outcome Dichotomized From an Underlying Continuous Variable in Clinical Trials

Markov-Restricted Analysis of Randomized Trials with Non-Monotone Missing Binary Outcomes

Information-Anchored Sensitivity Analysis: Theory and Application

Control-Based Imputation and Delta-Adjustment Stress Test for Missing Data Analysis in Longitudinal Clinical Trials

On inference of control-based imputation for analysis of repeated binary outcomes with missing data

Design of randomized clinical trials with a binary endpoint: Conditional versus unconditional analyses of a two‐by‐two table

Using Data Augmentation to Facilitate Conduct of Phase I-Ii Clinical Trials with Delayed Outcomes

Meta‐Analysis of Studies with Missing Data

Supplementary Data S2 from Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation

Handling Trial Participants with Missing Outcome Data when Conducting a Meta-Analysis: a Systematic Survey of Proposed Approaches.

Imputation methods for missing outcome data in meta-analysis of clinical trials

Abstract A6: A Global Sensitivity Test for Evaluating Hypotheses with Non- and Weakly Identifiable Statistical Models: an Application to Breast Cancer Outcomes

Semi-Parametric Sensitivity Analysis for Trials with Irregular and Informative Assessment Times

Handling incomplete outcomes and covariates in cluster-randomized trials: doubly-robust estimation, efficiency considerations, and sensitivity analysis

Analysis of a Binary Outcome Dichotomized from an Underlying Continuous Variable in Clinical Trials

Series 2-19-2009 Multiple Imputation Methods for Treatment Noncompliance and Nonresponse in Randomized Clinical Trials

Power Analysis for Cluster Randomized Trials with Binary Outcomes Modeled by Generalized Linear Mixed-Effects Models